2 results
Approved WMORecruiting
The primary objective of this study is to compare PFS with LY2875358 plus erlotinib therapy with erlotinibmonotherapy as first-line treatment in metastatic NSCLC patients with activating EGFR mutations who havedisease control after an 8-week lead-in…
Approved WMORecruiting
The main reason for conducting this study is to help in answering the following research question:• How tirzepatide compares to dulaglutide in preventing cardiovascular events in participants with type 2 diabetes and a higher risk of cardiovascular…